Peptide telehealth statistics 2026

The five numbers that matter most

1. 1

   On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee was scheduled to consider four peptide substance families — BPC-157, KPV, TB-500, and MOTs-C — for inclusion on the section 503A bulks list.

   U.S. Federal Register (Food and Drug Administration) · source · Accessed August 2, 2026 · Primary source

2. 2

   In 2026, 11% of U.S. adults said they were currently taking a GLP-1 medication for weight loss, up from 3% in 2024.

   Gallup · source · Accessed August 2, 2026 · Primary source

3. 3

   In 2026, 19% of current U.S. GLP-1 users reported using a compounded or custom-mixed version of the medicine, versus 68% using a brand-name product.

   Gallup · source · Accessed August 2, 2026 · Primary source

4. 4

   The global peptide therapeutics market was valued at USD 52.59 billion in 2025 and is projected to reach approximately USD 87.21 billion by 2035, a CAGR of 5.19% from 2026 to 2035.

   Precedence Research · source · Accessed August 2, 2026

5. 5

   In a national poll fielded October 27 to November 2, 2025, 17% of U.S. adults who had taken a GLP-1 said they got it from an online provider or website, compared with 76% who got it from a primary care provider or specialist.

   KFF · source · Accessed August 2, 2026 · Primary source

FDA compounding policy and the 503A list

Which peptides a licensed 503A pharmacy may legally compound is set by FDA policy, and that list changes. These are dates and process facts taken from the Federal Register, not interpretation.

1. The FDA announced a Pharmacy Compounding Advisory Committee meeting for July 23 and 24, 2026, to advise on bulk drug substances nominated for the section 503A bulks list.

   U.S. Federal Register (Food and Drug Administration) · source · Accessed August 2, 2026 · Primary source

2. On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee was scheduled to consider four peptide substance families — BPC-157, KPV, TB-500, and MOTs-C — for inclusion on the section 503A bulks list.

   U.S. Federal Register (Food and Drug Administration) · source · Accessed August 2, 2026 · Primary source

3. On July 24, 2026, the FDA's Pharmacy Compounding Advisory Committee was scheduled to consider three further peptide substance families — Emideltide (DSIP), Semax, and Epitalon — for inclusion on the section 503A bulks list.

   U.S. Federal Register (Food and Drug Administration) · source · Accessed August 2, 2026 · Primary source

4. The FDA's Pharmacy Compounding Advisory Committee met on December 4, 2024, to review the peptide bulk drug substances AOD-9604, CJC-1295, and Thymosin alpha-1 for the section 503A bulks list.

   U.S. Federal Register (Food and Drug Administration) · source · Accessed August 2, 2026 · Primary source

5. In its final rule published February 19, 2019, the FDA placed six bulk drug substances on the section 503A compounding list and declined to include four others.

   U.S. Federal Register (Food and Drug Administration) · source · Accessed August 2, 2026 · Primary source

6. In final guidance published January 7, 2025, the FDA ended its practice of sorting newly nominated bulk drug substances into Categories 1, 2, or 3 under its section 503A interim compounding policy.

   U.S. Federal Register (Food and Drug Administration) · source · Accessed August 2, 2026 · Primary source

7. In a notice published May 1, 2026, the FDA proposed not to include three bulk drug substances — semaglutide, tirzepatide, and liraglutide — on the section 503B bulks list.

   U.S. Federal Register (Food and Drug Administration) · source · Accessed August 2, 2026 · Primary source

Market size and growth

Forecasts published by the research firms that produced them. Projections are their authors' estimates, not Meto's, and different firms use different scopes and base years, which is why the numbers below do not agree with each other.

1. The global peptide therapeutics market was valued at USD 52.59 billion in 2025 and is projected to reach approximately USD 87.21 billion by 2035, a CAGR of 5.19% from 2026 to 2035.

   Precedence Research · source · Accessed August 2, 2026

2. The peptide therapeutics market is estimated at USD 49.68 billion in 2026 and is expected to reach USD 70.20 billion by 2031, a CAGR of 7.16% over the 2026–2031 forecast period.

   Mordor Intelligence · source · Accessed August 2, 2026

3. The global GLP-1 analogues market was calculated at USD 66.48 billion in 2025 and is forecast to reach approximately USD 1,062.90 billion by 2035, a CAGR of 31.94% from 2026 to 2035.

   Precedence Research · source · Accessed August 2, 2026

4. The global telehealth market was valued at USD 186.41 billion in 2025 and is projected to reach USD 1,272.81 billion by 2034, a CAGR of 24.60% over the 2026–2034 forecast period.

   Fortune Business Insights · source · Accessed August 2, 2026

5. The U.S. telehealth market is expected to grow from USD 52.77 billion in 2025 to USD 447.69 billion by 2035, a CAGR of 23.84%.

   Towards Healthcare · source · Accessed August 2, 2026

GLP-1 and peptide adoption

How many people are actually using these medicines, where they get them, and what is being spent. Usage and channel data only, with no claims about results.

1. In 2026, 11% of U.S. adults said they were currently taking a GLP-1 medication for weight loss, up from 3% in 2024.

   Gallup · source · Accessed August 2, 2026 · Primary source

2. In a national poll fielded October 27 to November 2, 2025, 18% of U.S. adults said they had ever used a GLP-1 agonist drug, including 12% who were currently using one.

   KFF · source · Accessed August 2, 2026 · Primary source

3. In 2026, 19% of current U.S. GLP-1 users reported using a compounded or custom-mixed version of the medicine, versus 68% using a brand-name product.

   Gallup · source · Accessed August 2, 2026 · Primary source

4. In a national poll fielded October 27 to November 2, 2025, 17% of U.S. adults who had taken a GLP-1 said they got it from an online provider or website, compared with 76% who got it from a primary care provider or specialist.

   KFF · source · Accessed August 2, 2026 · Primary source

5. In 2024, 26.5% of U.S. adults with diagnosed diabetes were using an injectable GLP-1 receptor agonist, according to the National Health Interview Survey.

   National Center for Health Statistics, CDC (NCHS Data Brief No. 537), abstract via PubMed · source · Accessed August 2, 2026 · Primary source

6. Medicare Part D claims for GLP-1 drugs rose from 4.8 million in 2019 to 21.8 million in 2024, a four-fold increase.

   KFF analysis of Medicare Part D data · source · Accessed August 2, 2026

7. Gross Medicare Part D spending on GLP-1 drugs reached $27.5 billion in 2024, a five-fold increase from 2019.

   KFF analysis of Medicare Part D data · source · Accessed August 2, 2026

Telehealth usage

How much care is delivered virtually in the US, and how consumer behavior has shifted since 2019.

1. Telemedicine use among U.S. physicians rose from 15.4% in 2019 to 86.5% in 2021, according to CDC's National Center for Health Statistics.

   U.S. Centers for Disease Control and Prevention, National Center for Health Statistics (NCHS Data Brief No. 493, February 2024) · source · Accessed August 2, 2026 · Primary source

2. In the first quarter of 2026, telehealth accounted for 5.51% of US medical claim lines, up from 5.01% in the fourth quarter of 2025.

   FAIR Health · source · Accessed August 2, 2026 · Primary source

3. In 2021, an estimated 37.0% of US adults reported using telemedicine in the past 12 months.

   Preventing Chronic Disease (US Centers for Disease Control and Prevention), National Health Interview Survey · source · Accessed August 2, 2026 · Primary source

4. In 2024, 44% of surveyed US consumers reported having had a virtual health visit in the previous 12 months, up from 42% in 2022.

   Deloitte · source · Accessed August 2, 2026 · Primary source

5. In the second quarter of 2025, 12.5% of eligible Medicare beneficiaries received a telehealth service.

   KFF · source · Accessed August 2, 2026 · Primary source

6. In 2024, US community health centers delivered 17.7 million telehealth visits, representing 13% of all their visits.

   KFF · source · Accessed August 2, 2026

7. In 2025, direct-to-consumer telehealth company Hims & Hers grew to more than 2.5 million subscribers, a 13% year-over-year increase.

   Hims & Hers Health, Inc. · source · Accessed August 2, 2026 · Primary source

Meto Health facts

We are the primary source for these. They are generated from the live catalog, so they match what the site actually sells on the last-updated date above. Cite them as Meto Health.

How we sourced this

1. 1

   Read, then re-checked. Every third-party figure was read on the linked page, then independently re-checked against that same page before publication.

2. 2

   Labelled by source type. Government, regulator, peer-reviewed, and company-filing sources are labeled primary; named research-firm report pages are labeled industry; anything relaying another party's figure is labeled secondary.

3. 3

   Omitted rather than rounded. Figures we could not confirm on a source page were omitted. A missing statistic is better than an unverifiable one.

4. 4

   Forecasts belong to their authors. Market forecasts are projections published by their authors, not predictions by Meto.

5. 5

   Re-verified quarterly. This page is re-verified quarterly; the last-updated date reflects the most recent pass.

Spotted an error or a stale figure? Email [email protected] and we will correct it. For how to evaluate any peptide provider, including us, see the vetting guide.